All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ICML 2019 | CLL12 study: should we treat asymptomatic, treatment naïve patients with ibrutinib?
Featured:
Petra LangerbeinsDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Petra Langerbeins from University of Cologne, Cologne, DE, about the CLL12 study. We asked: should we treat asymptomatic, treatment naïve patients with ibrutinib?
Petra Langerbeins explains how in the CLL 12 trial, non-chemo agent, ibrutinib was used, and showed a significant improvement in progression-free survival and event-free survival, and also and increased time to next CLL therapy. She mentions how the trial also shows a very good toxicity profile - something that other trials have failed to show.
ICML 2019 | CLL12 study: should we treat asymptomatic, treatment naïve patients with ibrutinib?
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?